From the Wires
2013 Could Be "The Year of The Point of Care Test": Kalorama
By: Marketwired .
Dec. 28, 2012 12:38 PM
NEW YORK, NY -- (Marketwire) -- 12/28/12 -- A number of developments bode well for tests that are performed in the healthcare settings, according to Kalorama information. The healthcare market research publisher said that the nearly $17 billion point of care test (POCT) market will see faster revenue growth in 2013 than tests sent to central labs for processing. The finding was made in its report, The World Market for Point of Care (POC) Diagnostics, authored by Sannes & Associates.
Point of care includes all decentralized clinical tests -- including those purchased over the counter such as glucose and pregnancy tests. It also includes tests performed outside of the central hospital lab, physician offices, clinics and other patient care sites. POCT products have not always succeeded at levels predicted in the past, but Kalorama's report finds a confluence of events that will benefit testing in POC locales versus traditional testing:
Kalorama sees growth at 1% faster than the IVD market overall due to these factors and others. Roche, Lifescan, Alere, Bayer and Abbott currently dominate point of care, but there are many other companies and new entrants. Kalorama identifies and profiles more than 140 of these POC companies in the report.
Kalorama's full-length study on the market for point of care testing, The World Market for Point of Care (POC) Diagnostics, contains a detailed segment breakdown of revenues, profiles companies in the market and discusses important trends. New POC innovations are also detailed in the report.
About Kalorama Information
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week